Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Vaxil Bio, (TASE: VAXL) a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM).

ImMucin is an immunotherapeutic treatment which educates the MM patient's immune system, particularly T-cells and antibodies, to attack MM cancer cells via a specific domain, termed signal peptide, of the tumor marker MUC1. This domain bears significant advantages as an immunotherapeutic modality. Immunotherapy as a cancer treatment modality has become an important field of medicine during the last two years. It has been the subject of great interest, as drugs that utilize the mechanisms of the immune system have been shown to produce results with far-reaching consequences, and have turned out to be "game changers" in the treatment of this disease.

"Orphan drug" designation is granted by the FDA in order to promote the clinical development of drugs and treatments with significant treatment potential against rare (fewer than 200,000 people in the US) life-threatening diseases. "Orphan drug" designation grants the exclusivity to market in the US for 7 years from the moment the approval is provided.

Dr. Lior Carmon, CEO and founder of Vaxil: "Despite notable recent advances in the treatment of MM, there are still no options resulting in full recovery from the disease. This is why there is a need for drugs that can delay the recurrence of the disease. ImMucin is intended to meet this need in MM patients with "minimal residual disease", turning their cancer into a chronic manageable disease. In light of the clinical results achieved thus far with ImMucin, manifested by a strong diversified immune response, we believe that ImMucin has great therapeutic and economic potential.

We have witnessed the growth of the immunotherapy sector and the great interest pharmaceutical giants have expressed in the promising clinical results of drugs that activate the immune system. Therefore, the FDA approval for ImMucin as an orphan drug, as well as similar approval by the European EMA, is an important milestone in the development of this unique treatment, both on regulatory and business levels."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How different types of bread impact cancer risk